NY-CORSEARCH
31.1.2020 13:02:09 CET | Business Wire | Press release
Corsearch, a trademark and brand protection solutions leader, is pleased to announce the acquisition of Pointer Brand Protection, a prominent provider of anti-counterfeiting and brand protection services. The acquisition further extends Corsearch’s fast-growing brand protection offering and provides a comprehensive new service for brand owners and legal professionals. For the first time, a consolidated suite of technologically advanced solutions will support the research, clearance, monitoring, investigative, and enforcement needs of the brand lifecycle.
From counterfeiting and piracy to gray trade and brand impersonation, estimates suggest that a staggering one in four online purchases involve brand infringement. With global eCommerce expected to reach 4.5 trillion U.S. dollars by 2021, the need for online brand protection to fight these threats has never been more urgent. It is an issue that is growing in tandem with total global trade, with some reports projecting that by 2022 counterfeiting and piracy could result in the loss of 4.2 trillion U.S. dollars and the endangerment of 5.4 million legitimate jobs.
A global problem needs global solutions, and the addition of Pointer Brand Protection into the Corsearch family aligns the technological capabilities and extensive networks of the entire group into a brand establishment and protection provider with unmatched coverage.
For many businesses, the digital environment has become so complex that establishing and protecting brands is too fragmented and time consuming to be manageable. To combat this effectively, brand owners and legal professionals require technological leadership and innovative solutions to implement a strong, proactive brand protection program. The Corsearch Brand Protection platform will provide an entirely new service offering which combines the very best teams, expertise, and technologies from both Pointer and from previous Corsearch acquisition, Yellow Brand Protection. In addition to Corsearch’s existing services, the new platform will provide brands with a full-service solution combining everything from trademark research and clearing to machine learning, automated marketplace enforcement, and end-to-end investigations. To fight infringements at their source, the new team will also include the largest China-based online brand protection department in the industry.
“Since 2008, Pointer has worked with hundreds of globally-renowned brands to protect them from infringement and abuse,” said Pointer CEO, Robert Stolk. “The industry is becoming more challenging every day and brands require technologies and services that can outpace that. Joining forces with Corsearch means securing the ability to innovate in a way that anticipates the needs of customers while also benefiting from Corsearch’s trusted industry presence.”
Corsearch’s CEO, Tobias Hartmann, commented, “We are thrilled to bring the brightest minds in online brand protection together and define the future of this industry. With this strategic acquisition Corsearch becomes the only provider to support the needs of IP and brand professionals throughout the trademark lifecycle.”
About Corsearch
Corsearch (www.corsearch.com ) is a leading provider of clearance and online brand protection solutions for trademark and brand professionals. With highly trained researchers, an expansive global content set, and customer-focused technology tools available through the Corsearch platform, Corsearch empowers its customers with powerful brand solutions in an increasingly complex business environment.
Founded in 1949 and headquartered in New York, Corsearch now has over 450 employees working across its 10 global offices. Corsearch has advised 43 of the world’s top 50 brands and has in excess of 5,000 clients around the world.
For more information please contact Stephen Stolfi, Chief Commercial Officer, or visit corsearch.com.
About Pointer
Pointer Brand Protection (https://pointerbrandprotection.com/ ) has been defending global brands from counterfeiting and brand abuse since 2008. With more than 120 employees working from offices in Amsterdam, Shanghai, New York, and London, Pointer is an industry leader in the fight against brand infringement. Pointer offers holistic and bespoke anti-counterfeiting solutions that include online-to-offline investigations, test purchasing services, dedicated brand protection analysts, and a proprietary software platform for the removal of infringements. Its mission is to clean the online marketplace in order to create safety for consumers, to increase the integrity of hard-working brands, and to reduce the negative societal impact of counterfeiting.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
